## Answer
(model generated chain of thought explanation)

Given the scenario, let's analyze the situation step by step:

1. **Patient Profile**: The patient is a 23-year-old woman with asthma, which means she has chronic obstructive pulmonary disease (COPD) and is likely experiencing acute exacerbation due to an asthma attack.

2. **Symptoms**: She presents with shortness of breath, wheezing, decreased breath sounds, and scattered end-expiratory wheezing over all lung fields. These symptoms are consistent with a severe asthma exacerbation.

3. **Treatment Initiated**: The patient is started on high-dose continuous inhaled albuterol, which is a common treatment for acute asthma exacerbations to help alleviate bronchospasm and improve airflow.

4. **Potential Adverse Effects of Albuterol**:
   - **A. Miosis (Pupil Constriction)**: Albuterol is a beta-2 adrenergic agonist that causes relaxation of the smooth muscles in the airways, leading to bronchodilation. One of its side effects can be miosis due to increased pupil size.
   - **B. Hypoglycemia**: There's no direct link between albuterol and hypoglycemia as a common adverse effect. Albuterol is not typically used for the treatment of diabetes or hypoglycemia.
   - **C. Hypokalemia (Low Potassium Levels)**: While beta-2 agonists like albuterol can cause changes in potassium levels due to increased cellular uptake, this is more commonly associated with long-term use rather than acute exacerbations.
   - **D. Urinary Frequency**: Albuterol can actually decrease urine output and increase urine concentration (nephrogenic diabetes insipidus), not urinary frequency.

Given the information above, the most likely adverse effect of starting high-dose continuous inhaled albuterol for this patient is miosis due to its beta-2 adrenergic agonist properties. This makes option A the correct answer.

The final answer is: $\boxed{A}$